ARTICLE | Company News
MabCure, Biotech Investment deal
December 5, 2011 8:00 AM UTC
MabCure granted Biotech Investment an exclusive, worldwide license to undisclosed MabCure hybridoma clones producing antibodies against prostate cancer. MabCure received $500,000 up front and is eligi...